Prager R, Schernthaner G, Kostner G M, Mühlhauser I, Zechner R, Dorda W
Atherosclerosis. 1982 Jun;43(2-3):321-7. doi: 10.1016/0021-9150(82)90032-6.
The effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B, and LCAT activity was investigated in 16 hyperlipidemic, non-insulin-dependent diabetes, who were treated for 8 weeks with either placebo or bezafibrate in a double-blind cross-over design. Bezafibrate induced a significant decrease in plasma triglycerides (P less than 0.01), cholesterol (P less than 0.05), VLDL triglycerides (P less than 0.05) and VLDL cholesterol (P less than 0.01), and a significant increase in HDL cholesterol (P less than 0.01), whereas LDL cholesterol remained unchanged. The apolipoprotein AI/apolipoprotein B ratio increased significantly (P less than 0.05), although individual changes in these apolipoproteins were not significant. Apolipoprotein AII increased significantly (P less than 0.05), although individual changes in these apolipoproteins were not significant. Apolipoprotein AII increased significantly (P less than 0.0001) and the apolipoprotein AI/apolipoprotein AII ratio decreased (P less than 0.0001), indicating an increase in the HDL3 rather than the HDL2 fraction. No significant change in LCAT activity was observed.
在16名高脂血症非胰岛素依赖型糖尿病患者中，采用双盲交叉设计，研究了苯扎贝特对血脂、脂蛋白、载脂蛋白AI、AII和B以及卵磷脂胆固醇酰基转移酶（LCAT）活性的影响。这些患者分别接受了8周的安慰剂或苯扎贝特治疗。苯扎贝特可使血浆甘油三酯（P<0.01）、胆固醇（P<0.05）、极低密度脂蛋白甘油三酯（P<0.05）和极低密度脂蛋白胆固醇（P<0.01）显著降低，高密度脂蛋白胆固醇显著升高（P<0.01），而低密度脂蛋白胆固醇保持不变。载脂蛋白AI/载脂蛋白B比值显著升高（P<0.05），尽管这些载脂蛋白的个体变化不显著。载脂蛋白AII显著升高（P<0.05），尽管这些载脂蛋白的个体变化不显著。载脂蛋白AII显著升高（P<0.0001），载脂蛋白AI/载脂蛋白AII比值降低（P<0.0001），表明高密度脂蛋白3而非高密度脂蛋白2组分增加。未观察到LCAT活性的显著变化。
